⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Capecitabine

کپسیتابین

⚠ Unverified

🎗️ Antineoplastic And Immunomodulating AgentsAntimetabolite (fluorouracil prodrug)

🤰 Pregnancy:Dangerous / avoid 🤱 Breastfeeding:Dangerous / avoid 👶 Children:Safety not established 👴 Older adults:No specific problem stated ⚥ Females & males of reproductive potential:Use with caution 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved generic (ANDA) ANDA210203 ATC L01BC06

Market / country: 🇺🇸 USA

Xeloda (US)

🧮 Dose calculator

Disease / regimen

Colorectal cancer · Regimen source: FDA Capecitabine · 2.1

• Only under an oncologist; dose is adjusted by response and toxicity. FDA Capecitabine · 2
• Twice daily about 12 h apart within 30 min after a meal; days 1–14 of each 21-day cycle. Round to the nearest 150 mg. CrCl 30–50: reduce by 25%; <30 not established. FDA Capecitabine · 2.7 FDA Capecitabine · 2.6
• With oxaliplatin: 1000 mg/m² twice daily. FDA Capecitabine · 2.2

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ History of severe hypersensitivity to fluorouracil or capecitabine. FDA Capecitabine · 4

Warnings

• Boxed warning: bleeding and raised INR with warfarin (monitor INR frequently). DPD deficiency: severe or fatal toxicity. Diarrhoea, hand-foot syndrome. FDA Capecitabine · Boxed Warning FDA Capecitabine · 5

Renal adjustment

• eGFR < 51: CrCl 30–50: reduce dose by 25%; <30 dose not established. FDA Capecitabine · 2.6

Formulations

150 mg tablet — tablet 🇺🇸 USA FDA Capecitabine · 3
500 mg tablet — tablet 🇺🇸 USA FDA Capecitabine · 3

👥 Special populations

🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Capecitabine · 8.1
“Risk Summary Based on findings in animal reproduction studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , capecitabine can cause fetal harm when administered to a pregnant woman.”
🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Capecitabine · 8.2
“Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with capecitabine and for 1 week after the last dose.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Capecitabine · 8.4
“The safety and effectiveness of capecitabine in pediatric patients have not been established.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Capecitabine · 8.5
“No overall differences in efficacy were observed comparing older versus younger patients with colorectal cancer, gastric, esophageal or gastrointestinal junction cancer, or pancreatic cancer using the approved recommended dosages and treatment regimens.”
⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Capecitabine · 8.3
“Contraception Females Advise females of reproductive potential to use effective contraception during treatment with capecitabine and for 6 months after the last dose.”

🔗 Reference links

FDA (approval record)ANDA210203
DailyMed (FDA label)FDA Capecitabine
MedlinePlus (NIH)Capecitabine
WHO ATC/DDDL01BC06
Darooyab (Iran)Capecitabine

🇮🇷 Registered in Iran Darooyab · G-961/Capecitabine

Dosage forms with Iranian generic codes, per Darooyab.

02492 · CAPECITABINE 150MG TAB · قرص کاپسیتابین ۱۵۰ میلی‌گرم
02493 · CAPECITABINE 500MG TAB · قرص کاپسیتابین ۵۰۰ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Capecitabine · 3 FDA Capecitabine · 2.1 FDA Capecitabine · 2 FDA Capecitabine · 2.7 FDA Capecitabine · 2.6 FDA Capecitabine · 2.2 FDA Capecitabine · 4 FDA Capecitabine · Boxed Warning FDA Capecitabine · 5 FDA Capecitabine · SPL approval / marketing category FDA Capecitabine · 8.1 FDA Capecitabine · 8.2 FDA Capecitabine · 8.4 FDA Capecitabine · 8.5 FDA Capecitabine · 8.3
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-961/Capecitabine
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Anastrozole Letrozole Tamoxifen